CONSERVATIVE APPROACHES TO CORRECTING POSTMENOPAUSAL UROGENITAL DISORDERS

Objective. To estimate changes in the degree of postmenopausal urogenital disorders (UGD) during trioginal therapy. Subjects and methods. Sixty-nine postmenopausal patients (mean age 58.46+3.59 years) with UGD were examined and enrolled in the trial. The patients were treated with vaginal trioginal by the scheme: 2 capsules simultaneously once daily for 14 days, then 1 capsule daily for 7 days, thereafter the patients took 1 capsule twice weekly for 2 months. Changes in the degree of UGD were estimated using questionnaires and the data of instrumental and laboratory studies, including calculation of karyopyknotic index (KPI), at baseline and at every subsequent visits. The magnitude of psychoemotional, autonomic vascular, and urogenital symptoms and metabolic disturbances was estimated using the Kupperman index (KI). A quality of life questionnaire was separately applied in conjunction with the evaluation of dysuria (Scale S and Scale L). Results. The symptoms of urinary incontinence were observed to be reducedjust two weeks after therapy initiation. During the therapy, there was a 2.8-fold improvement in quality of life (L) and pronounced positive changes in KI. The mean KPI increased by more than twice. There were positive changes in pH level. During the therapy, all the patients had no signs of endometrial thickening, as evidenced by ultrasound study. All the investigation participants completed a trioginal treatment cycle in accordance with the study design without changing the therapy regimen. Conclusion. The good tolerability, no adverse events of, and satisfaction with the performed treatment permit trioginal to be recommended for use as a highly effective and safe drug to correct postmenopausal UGD.

postmenopause, urogenital disorders, urogenital atrophy, menopausal disorders, menopausal hormone therapy, urinary incontinence, estriol, lactobacilli, vaginal biocenosis